Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database

Human Mutation

Volumn 28, Issue 6, 2007, Pages 622-629

  Petitjean, Audrey ^a   Mathe, Ewy ^a,b   Kato, Shunsuke ^c   Ishioka, Chikashi ^c   Tavtigian, Sean V ^a   Hainaut, Pierre ^a   Olivier, Magali ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Functional assay; Missense mutation; p53; TP53; Transactivation

Indexed keywords

MUTANT PROTEIN; NUCLEOTIDE; PROTEIN P53;

ARTICLE; CANCER CLASSIFICATION; DATA ANALYSIS; DATA BASE; DISEASE SEVERITY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; MUTANT; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SYSTEMATIC REVIEW; TRANSACTIVATION; TUMOR; WILD TYPE;

AGE OF ONSET; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; GERM-LINE MUTATION; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248379012     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20495     Document Type: Article

References (23)

1. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. 2001. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621-4628.
2. Brachmann RK, Vidal M, Boeke JD. 1996. Dominant-negative p53 mutations selected in yeast hit cancer hotspots. Proc Natl Acad Sci USA 93:4091-4095.
3. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, Yi SY, Brachmann RK. 2007. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28:289-298.
4. Denissenko MF, Pao A, Tang M, Pfeifer GP. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430-432.
5. Hainaut P, Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137.
6. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M. 1994. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145:702-714.
7. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424-8429.
8. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872.
9. Lunter G, Hein J. 2004. A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics 20(Suppl 1):I216-I223.
10. Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
11. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34:1317-1325.
12. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P. 2001. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20:3533-3540.
13. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860.
14. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614.
15. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. 2003. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643-6650.
16. Olivier M, Hussain SP, Caron dF, Hainaut P, Harris CC. 2004. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157:247-270.
17. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL. 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167.
18. Pan Y, Haines DS. 2000. Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 19:3095-3100.
19. Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T. 1999. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 18:2451-2459.
20. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, Evans DG, Birch JM. 1997. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14:865-871.
21. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
22. Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S. 2006. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130:73-79.
23. Zajac V, Tomka M, Ilencikova D, Majek P, Stevurkova V, Kirchhoff T. 2000. A double germline mutations in the APC and p53 genes. Neoplasma 47:335-341.